Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
2024年8月27日 - 5:01AM
ビジネスワイヤ(英語)
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that it will present data at the International League Against
Epilepsy (ILAE) 15th Annual European Epilepsy Congress which is
taking place in Rome, Italy from September 7-11, 2024.
“ILAE is one of the premier medical organizations in the
epilepsy space and we look forward to participating in this
important meeting, which brings together key opinion leaders from
across Europe and the rest of world. As we prepare for the
initiation of our global Phase 3 program this year, this conference
will help us continue to broaden our engagement with potential
investigators and gain important insights,” stated Dr. Randall
Kaye, Longboard’s Chief Medical Officer. “We are pleased that our
PACIFIC study open label extension interim data was accepted as a
late breaker for this conference, and we look forward to discussing
these data as well as additional data that highlights the potential
of bexicaserin for individuals living with a broad range of
Developmental and Epileptic Encephalopathies, or DEEs.”
EVENT DETAILS:
LATE BREAKER Title: Safety and Tolerability of
Bexicaserin in Adolescents and Adults with Developmental and
Epileptic Encephalopathies: Interim Results of the Phase 1b/2a
PACIFIC Study Open-Label Extension (OLE) Event Type:
In-Person Posters Poster Number: P082
Title: Efficacy and Safety of Bexicaserin (LP352) in
Adolescent and Adult Participants with Developmental and Epileptic
Encephalopathies: Results of The Phase 1b/2a PACIFIC Study
Session: Platform Session – Drug Therapy Event Type:
Platform Session Presentation Time: Sunday, September 8,
2024, from 12:30 PM – 12:38 PM CET
Title: Bexicaserin has Negligible CYP Or P-glycoprotein
Interaction Potential, Minimizing Therapeutic Complexity In
Epilepsy Patients with a High Burden of Polypharmacy Event
Type: In-Person Posters Poster Number: P321
Title: A Phase 1 Study Of 5-HT2C Superagonist LP352 Shows
Robust Brain Penetration, a Strong Correlation Between Plasma and
CSF Pharmacokinetics and QEEG Changes Reflecting Receptor
Engagement Event Type: In-Person Posters Poster
Number: P262
Title: Bexicaserin, A 5-HT2C Superagonist, has Broad
Antiepileptic Activity in Preclinical Seizure Models Event
Type: In-Person Posters Poster Number: P261
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard plans to advance bexicaserin (LP352), an oral,
centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor
superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor
subtypes, into a global Phase 3 program. The FDA has granted
Breakthrough Therapy designation for bexicaserin for the treatment
of seizures associated with Developmental and Epileptic
Encephalopathies (DEEs) for patients two years of age and older.
Earlier this year, Longboard reported positive topline data from a
Phase 1b/2a clinical trial (the PACIFIC Study) evaluating
bexicaserin in participants with DEEs. Longboard is also evaluating
LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P)
receptor subtypes 1 and 5 modulator, which is in development for
the potential treatment of rare neuroinflammatory conditions.
Longboard recently completed a Phase 1 single-ascending dose (SAD)
clinical trial for LP659 in healthy volunteers.
Bexicaserin and LP659 are investigational compounds that are not
approved for marketing by the U.S. Food and Drug Administration
(FDA) or any other regulatory authority.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. In
some cases, you can identify forward-looking statements by words
such as “focus”, “will”, “look forward to”, “prepare for”,
“potential”, “working to”, “designed to”, “plans”, “potential” or
the negative, plural or other tenses of these words, references to
future dates or time periods, or other comparable language, and
they may include, without limitation, statements about Longboard’s
presentations, product candidates, clinical and preclinical
programs, focus and work. For such statements, Longboard claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Longboard’s
expectations. Factors that could cause actual results to differ
materially from those stated or implied by Longboard’s
forward-looking statements are disclosed in Longboard’s filings
with the Securities and Exchange Commission (SEC). These
forward-looking statements represent Longboard’s judgment as of the
time of this release. Longboard disclaims any intent or obligation
to update these forward-looking statements, other than as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240826889335/en/
Megan E. Knight VP, Head of Investor Relations
IR@longboardpharma.com 858.789.9283
Longboard Pharmaceuticals (NASDAQ:LBPH)
過去 株価チャート
から 8 2024 まで 9 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
過去 株価チャート
から 9 2023 まで 9 2024